Armata Pharmaceuticals
ARMP
17 hedge funds and large institutions have $7.25M invested in Armata Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 5 closing their positions.
68% more capital invested
Capital invested by funds: $4.32M → $7.25M (+$2.93M)
0.1% more ownership
Funds ownership: 4.78% → 4.88% (+0.1%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
15% less funds holding
Funds holding: 20 → 17 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$393K |
| 2 |
Edgewood Management
Greenwich,
Connecticut
|
+$209K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$54.6K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$50.3K |
| 5 |
BlackRock
New York
|
+$22.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$89K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$43K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$36.4K |
| 4 |
SSB
Sandy Spring Bank
Olney,
Maryland
|
-$4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.62K |
ARMP Hedge Fund Activity: Q4 2021 in Review
17 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q4 2021, worth a combined $7.25M — up 68% from $4.32M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ARMP and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $393K. The largest seller was Renaissance Technologies, cutting an estimated $89K.
- 17 institutional investors held Armata Pharmaceuticals (ARMP) as of Q4 2021, down from 20 in Q3 2021.
- Funds reported $7.25M of Armata Pharmaceuticals stock for Q4 2021, up 68% quarter-over-quarter.
- 2 funds opened new Armata Pharmaceuticals positions in Q4 2021 and 5 closed out, a net change of -3 holders.
- The largest Armata Pharmaceuticals buyer in Q4 2021 was Vanguard Group, an estimated $393K added.
- The largest Armata Pharmaceuticals seller in Q4 2021 was Renaissance Technologies, an estimated $89K sold.
Based on aggregated 13F filings for Q4 2021.